Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular GLUE degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

  • Morgan Stanley 23 rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.
  • Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 15, 2025, at 9:00 a.m. ET.

A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com , and an archived version will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com .

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GLUE
The Conversation (0)
Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.

The Gummy Project

Potent Ventures Establishes Partnership with Leading Shark Conservation Group "OCEARCH" In Preparation for Launch of the Gummy Project

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce that the Company has established a partnership with OCEARCH, a global non-profit organization conducting unprecedented research on shark populations in order to accelerate the ocean's return to balance and abundance.

  • OCEARCH is a global non-profit conducting unprecedented research on sharks that will be supported by The Gummy Project's initial product line of shark gummies
  • The Company's keystone species* strategy is designed to engage consumers and deliver tangible conservation outcomes
  • Partnership with OCEARCH will deliver education and consumer engagement content, while delivering data to manage threatened shark populations

"We are absolutely thrilled to have established this significant partnership with OCEARCH (www.ocearch.org), and the previously announced 'Bee Conservancy (www.thebeeconservancy.org),' both of which are essential to the Gummy Project's "Keystone" species strategy, helping to raise awareness of endangered "Keystone" species that are crucial to the planet's ecosystems," said Mr. Charlie Lamb, CEO of the Company "The Gummy Project is purpose driven, supporting endangered, "Keystone" species, one gummy at a time - and by doing so, we are supporting some of the world's most important ecosystems while providing a healthier and more sustainable alternative to the typical sugar-packed gummy - and very importantly, engaging consumers with a feel-good marketing strategy."

Keep reading...Show less
The Gummy Project

Potent Ventures Establishes New Partnership with New York Based "The Bee Conservancy" to Enact Its Purpose-Driven Keystone Species Strategy for the Gummy Project

Potent Ventures Inc. (CSE: POT) (FSE: 0OS2) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce that it has established a partnership with "The Bee Conservancy," forming the foundation for its purpose-driven endangered Keystone Species product marketing strategy for The Gummy Project's initial gummy product line, featuring Bees and Sharks.

  • The Bee Conservancy partnership paves way for the launch of The Gummy Project purpose driven strategy, delivering consumer reach, educational content and co-marketing across multiple communications channels
  • The Gummy Project to Champion endangered Keystone Species, supporting global efforts to raise awareness and protect endangered Keystone Species through the sale of high-quality gummy products and engaging storytelling
  • Bee and Shark Gummies to lead the way for consumer launch and building purpose driven conservation partnerships

"Our new partnership with "The Bee Conservancy" is fundamental to the The Gummy Project's commitment to helping raise awareness of endangered species that are crucial to the world's ecosystems," said Mr. Charlie Lamb, CEO of the Company. "We will be working collaboratively with the Bee Conservancy to align our Keystone Species strategy across multiple channels including, packaging, education, media promotion, social influencers, events and more as we support their efforts to protect bees, which are critical to all life on this planet."

Keep reading...Show less
The Gummy Project

Potent Ventures Appoints Seasoned Chief Marketing Officer in Preparation for Launch of the Gummy Project

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce that the Company has appointed Mr. Anthony Gindin to the role of Chief Marketing Officer as the Company prepares to enter the $20 billion (CAD)1 gummy industry.

  • Mr. Anthony Gindin, global marketing strategist and plant-based entrepreneur to lead brand development of gummy product line
  • Company also announces launch of The Gummy Project's splash page at ir.shopgummies.com

"We are thrilled to have Anthony Gindin join the team," said Charlie Lamb, Potent President and CEO. "His knowledge in the plant based sector, from market resarch to product sourcing, brand positioning, digital presence, sales and marketing through to market launch, provides our group with the expertise to expedite our entry into the low-sugar gummy sector."

Keep reading...Show less
Potent Venture Logo

The Gummy Project to Adopt Purpose-Driven Endangered Keystone Species Strategy to Engage Consumers with Launch of Shark and Bee Shaped Gummy Products

  • Gummy and Jelly Industry valued at $20 billion1
  • The Gummy Project to Champion endangered Keystone Species, supporting global efforts to raise awareness and protect endangered Keystone Species through the sale of high-quality gummy products and engaging storytelling
  • Shark Gummies and Bee Gummies to lead the way for consumer launch and conservation partnerships

Further to its press release dated December 22, 2021 announcing a name change from Potent Ventures Inc. (CSE: POT) (FSE: 0OS2) (OTCQB: POTVF) ("Potent" or the "Company") to the Gummy Project Inc. (the "Gummy Project"), effective upon completion of the "change of business", the Company is excited to announce its purpose-driven endangered Keystone Species product marketing strategy for the Gummy Project's initial gummy product line.

Keep reading...Show less
comfort inn langley bc

Phyto Extractions Inc. Officially Launches Shatter For Adult-Use Market

Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(FRA:D2EP) ("Phyto Extractions™or the "Company") strives to continuously bring consumers new and innovative products to enhance their experience and overall enjoyment. Shatter is Phyto Extractions™ newest product category, with three new high THC extract offerings produced from single-source strains (local to BC and ON). Available in three highly popular strains including: Blue Gorilla OG, Pink Kush and D Bubba, all Phyto Extractions™ shatter is extracted and processed in a controlled laboratory environment to prevent contaminants, living up to the brands promise of offering consumers products that are free of additives and synthetic fillers

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×